Prevail Therapeutics Inc. Common Stock
PRVL
PRVL was delisted on the 21st of January, 2021.
93 hedge funds and large institutions have $648M invested in Prevail Therapeutics Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 41 funds opening new positions, 16 increasing their positions, 27 reducing their positions, and 24 closing their positions.
115% more capital invested
Capital invested by funds: $302M → $648M (+$346M)
71% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 24
22% more funds holding
Funds holding: 76 → 93 (+17)
41% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 27
77% less call options, than puts
Call options by funds: $3.68M | Put options by funds: $15.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AAM
Alpine Associates Management
Palm Beach,
Florida
|
+$10.9M |
| 2 |
TAL
TIG Advisors LLC
New York
|
+$8.99M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
+$7.55M |
| 4 |
Millennium Management
New York
|
+$6.64M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$3.52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$19.5M |
| 2 |
HighTower Advisors
Chicago,
Illinois
|
-$11.5M |
| 3 |
BlackRock
New York
|
-$9.81M |
| 4 |
Morgan Stanley
New York
|
-$7.86M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.87M |
PRVL Hedge Fund Activity: Q4 2020 in Review
93 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Prevail Therapeutics Inc. Common Stock (PRVL) for Q4 2020, worth a combined $648M — up 115% from $302M a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new PRVL positions and 24 closed out — a net gain of 17 holders — while 16 added to existing stakes and 27 trimmed.
The largest buyer was Alpine Associates Management, opening a new position worth an estimated $10.9M. The largest seller was RA Capital Management, exiting entirely with an estimated $19.5M sold.
- 93 institutional investors held Prevail Therapeutics Inc. Common Stock (PRVL) as of Q4 2020, up from 76 in Q3 2020.
- Funds reported $648M of Prevail Therapeutics Inc. Common Stock stock for Q4 2020, up 115% quarter-over-quarter.
- 41 funds opened new Prevail Therapeutics Inc. Common Stock positions in Q4 2020 and 24 closed out, a net change of +17 holders.
- The largest Prevail Therapeutics Inc. Common Stock buyer in Q4 2020 was Alpine Associates Management, an estimated $10.9M added.
- The largest Prevail Therapeutics Inc. Common Stock seller in Q4 2020 was RA Capital Management, an estimated $19.5M sold.
Based on aggregated 13F filings for Q4 2020.